Anthony P. Gulati

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah et al. · The Lancet · 2020 · 1.8K citations · Full text

Epidemiology, Cancer Epidemiology, Medicine +11

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

Robert L. Fine, Anthony P. Gulati, Benjamin A. Krantz et al. · Cancer Chemotherapy and Pharmacology · 2013 · 251 citations

Columbia University Experience, Pancreatic Cancer, Medicine +8

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19

Michael A. Thompson, Jeffrey P. Henderson, Pankil Shah et al. · JAMA Oncology · 2021 · 184 citations · Full text

High Response Rates and Prolonged Survival in Patients With Corticotroph Pituitary Tumors and Refractory Cushing Disease From Capecitabine and Temozolomide (CAPTEM)

Brad E. Zacharia, Anthony P. Gulati, Jeffrey N. Bruce et al. · Neurosurgery · 2013 · 85 citations

Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors.

Robert L. Fine, Anthony P. Gulati, Dawn Tsushima et al. · Journal of Clinical Oncology · 2014 · 72 citations

Pathology, Ongoing Pfs, Metronomic Chemotherapy +17